In advanced cancer, various immune checkpoint inhibitors, including programmed cell death 1 (PD-1), its ligand PD-L1, and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), have achieved promising oncological improvements [15,16,17,18]. This evidence concerns the gene CD274 and cancer.